Quarterly Report · 10-Q

Nuvalent, Inc.

Quarterly Report

Filed May 7, 2026Accepted May 7, 2026, 6:38 AM EDTCIK 1861560Accession 0001861560-26-000021

Company context

Nuvalent (NASDAQ: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, Nuvalent develops innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

Historical securities (1)

NUVLNASDAQ · EQUITY · Historical · closed Jul 15, 2026

Recent company filings

Registered securities in this filing

NUVALENT, INC. · 10-Q · Filed 2026-05-07

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Class A Common Stock, par value $0.0001 per share

Symbol: NUVL
Exchange: NASDAQ
Classification: COMMON
Status: Historical · closed Jul 15, 2026

Filing context

Context: C_2e309af0-f646-4a40-a68e-168146b30e31

Dimensions: Not supplied

Accession 000186156026000021 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence

As filedOpen full document ↗

Get the free weekly BCS email.